Helix BioPharma Income Statement

Financials in millions CAD. Fiscal year is August - July.

Millions CAD. Fiscal year is Aug - Jul.

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jul '26 Jul 31, 2026	Jul '25 Jul 31, 2025	Jul '24 Jul 31, 2024	Jul '23 Jul 31, 2023	Jul '22 Jul 31, 2022
Selling, General & Admin	2.02	1.84	3.26	1.05	1.5
Research & Development	1.62	3.56	5.98	5.28	4.54
Operating Expenses	3.64	5.4	9.24	6.33	6.04
Operating Income	-3.64	-5.4	-9.24	-6.33	-6.04
Interest Expense	-0.18	-0.01	-0.01	-0.01	-0.02
Interest & Investment Income	-	0.02	0.03	0.05	0
Currency Exchange Gain (Loss)	-0.12	-0.14	-0.05	-0	-0.01
Other Non Operating Income (Expenses)	0.59	0.31	-	-	0
EBT Excluding Unusual Items	-3.35	-5.22	-9.26	-6.3	-6.06
Gain (Loss) on Sale of Assets	-	0.02	-	0.01	-
Other Unusual Items	-	-	-	-	-0.5
Pretax Income	-3.35	-5.21	-9.26	-6.29	-6.56
Earnings From Continuing Operations	-3.35	-5.21	-9.26	-6.29	-6.56
Net Income to Company	-3.35	-5.21	-9.26	-6.29	-6.56
Net Income	-3.35	-5.21	-9.26	-6.29	-6.56
Net Income to Common	-3.35	-5.21	-9.26	-6.29	-6.56
Net Income Growth	-	-	-	-	-
Shares Outstanding (Basic)	76	56	44	39	30
Shares Outstanding (Diluted)	76	56	44	39	30
Shares Change	36.81%	25.29%	15.11%	29.26%	8.41%
EPS (Basic)	-0.04	-0.09	-0.21	-0.16	-0.22
EPS (Diluted)	-0.04	-0.09	-0.21	-0.16	-0.22
EPS Growth	-	-	-	-	-

Additional Metrics

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jul '26 Jul 31, 2026	Jul '25 Jul 31, 2025	Jul '24 Jul 31, 2024	Jul '23 Jul 31, 2023	Jul '22 Jul 31, 2022
Free Cash Flow	-4.32	-3.83	-5.23	-5.54	-6.51
Free Cash Flow Per Share	-0.06	-0.07	-0.12	-0.14	-0.22
EBITDA	-3.64	-5.39	-9.23	-6.31	-6.03
D&A For EBITDA	0	0.01	0.01	0.01	0.01
EBIT	-3.64	-5.4	-9.24	-6.33	-6.04